BBIO
BridgeBio Pharma, Inc.
Key Financials
Revenue
$502.1M
↑ 126.3%
Net Income
$-69000
N/A
Operating Income
$-523411000
↑ 11.7%
Total Assets
$936.0M
↑ 1.8%
Total Liabilities
$3.0B
↑ 26.7%
EPS (Diluted)
$-3.78
↓ 31.3%
Shareholders' Equity
$-2086610000.00
↓ 42.1%
Cash & Equivalents
$570.1M
↓ 16.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 4/16/2026 | View on SEC |
| 4 | 4/13/2026 | View on SEC |
| 144 | 4/9/2026 | View on SEC |
| SCHEDULE 13D/A | 4/2/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/20/2026 | View on SEC |
| 4 | 3/20/2026 | View on SEC |
| 4 | 3/19/2026 | View on SEC |
| 4 | 3/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BBIO |
| Company Name | BridgeBio Pharma, Inc. |
| CIK | 1743881 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 391-9740 |